Soleno Therapeutics, Inc.
SLNO
$73.64
$0.380.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 685.26% | 519.08% | 149.32% | 89.95% | 36.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 376.93% | 332.00% | 137.87% | 101.04% | 54.01% |
| Operating Income | -376.93% | -332.00% | -137.87% | -101.04% | -54.01% |
| Income Before Tax | -351.04% | -295.33% | -129.92% | -94.88% | -62.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -351.04% | -295.33% | -129.92% | -94.88% | -62.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -351.04% | -295.33% | -129.92% | -94.88% | -62.00% |
| EBIT | -376.93% | -332.00% | -137.87% | -101.04% | -54.01% |
| EBITDA | -396.95% | -353.54% | -147.92% | -109.09% | -58.62% |
| EPS Basic | -43.20% | -2.66% | 16.91% | 5.46% | 1.65% |
| Normalized Basic EPS | -49.62% | -2.14% | 22.54% | 9.65% | 11.90% |
| EPS Diluted | -43.35% | -2.79% | 16.76% | 5.46% | 1.65% |
| Normalized Diluted EPS | -49.62% | -2.14% | 22.54% | 9.65% | 11.90% |
| Average Basic Shares Outstanding | 144.33% | 270.96% | 211.70% | 145.75% | 96.08% |
| Average Diluted Shares Outstanding | 144.33% | 270.96% | 211.70% | 145.75% | 96.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |